Henlius 2025 Global R&D Day: Harnessing the Power of Innovation to Propel Global Strategy to New Heights

In addition to its innovative pipeline and portfolio, the company highlighted its three innovative technology platforms, including Hinova TCE (tri-specific T-cell engager) platform for solid tumors, the proprietary ADC platform Hanjugator™, and the AI-driven drug discovery platform HAI Club, which have formed a collaborative R&D matrix to accelerate the development of differentiated therapies. Meanwhile, Henlius is strategically advancing the development of its proprietary hyaluronidase Henozye™ and subcutaneous injection technologies, accelerating formulations for novel drugs and biosimilars while extending product lifecycles.
Comunicato Precedente

next
Comunicato Successivo

next
SHANGHAI, (informazione.it - comunicati stampa - salute e benessere)

In addition to its innovative pipeline and portfolio, the company highlighted its three innovative technology platforms, including Hinova TCE (tri-specific T-cell engager) platform for solid tumors, the proprietary ADC platform Hanjugator™, and the AI-driven drug discovery platform HAI Club, which have formed a collaborative R&D matrix to accelerate the development of differentiated therapies. Meanwhile, Henlius is strategically advancing the development of its proprietary hyaluronidase Henozye™ and subcutaneous injection technologies, accelerating formulations for novel drugs and biosimilars while extending product lifecycles.

Globalization remains a key focus for Henlius, with Japan prioritized as a strategic market under its "Internationalization 2.0" strategy. Henlius leverages Japan's aging population and regulatory environment to advance clinical trials for HLX22 and serplulimab (anti-PD-1), aiming to build an end-to-end value chain from R&D to commercialization. At the "Partnering for Success" panel, 2022 Nobel Laureate Prof. Carolyn Bertozzi highlighted the promise of sialoglycan-targeting therapies in oncology and immunology. Through the collaboration with Henlius, the development of human sialidase fusion protein HLX79 (E-602) has been accelerated. Industry leaders underscored Henlius' integrated capabilities in antibody development, clinical execution, and global-quality manufacturing as key drivers for forging high-impact alliances. Driven by "trust-driven" partnerships, the company expands its therapeutic ecosystem globally.

The event concluded with a call for industry-wide collaboration to bridge the preclinical-clinical gap, leveraging AI and data-driven strategies to accelerate patient-centric innovation. In 2025, Henlius aims to transform technological advancements into clinical value, reinforcing China's role in global biopharma.

Cision View original content:https://www.prnewswire.co.uk/news-releases/henlius-2025-global-rd-day-harnessing-the-power-of-innovation-to-propel-global-strategy-to-new-heights-302431347.html

Ufficio Stampa

 PR Newswire (Leggi tutti i comunicati)
209 - 215 Blackfriars Road
LONDON United Kingdom

Allegati
Non disponibili